Small molecule · Antagonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) · developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Enpatoran is an orally bioavailable dual antagonist of Toll-like receptors 7 and 8, binding and inhibiting TLR7/8-mediated signaling that drives pro-inflammatory cytokine production. It is being studied in systemic lupus erythematosus and cutaneous lupus erythematosus.
Summary written with AI from the sources listed at the end of this page.
Cutaneous Lupus ErythematosusSystematic Lupus Erythematosus
Updated Nov 8, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →